Dataset Information

Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques.

ABSTRACT: Several HIV-1 and SIV vaccine candidates have shown partial protection against viral challenges in rhesus macaques. However, the protective efficacy of vaccine-elicited polyclonal antibodies has not previously been demonstrated in adoptive transfer studies in nonhuman primates. In this study, we show that passive transfer of purified antibodies from vaccinated macaques can protect naive animals against SIVmac251 challenges. We vaccinated 30 rhesus macaques with Ad26-SIV Env/Gag/Pol and SIV Env gp140 protein vaccines and assessed the induction of antibody responses and a putative protective signature. This signature included multiple antibody functions and correlated with upregulation of interferon pathways in vaccinated animals. Adoptive transfer of purified immunoglobulin G (IgG) from the vaccinated animals with the most robust protective signatures provided partial protection against SIVmac251 challenges in naive recipient rhesus macaques. These data demonstrate the protective efficacy of purified vaccine-elicited antiviral antibodies in this model, even in the absence of virus neutralization.

SUBMITTER: Alter G

PROVIDER: S-EPMC7534693 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques.

Alter Galit G Yu Wen-Han WH Chandrashekar Abishek A Borducchi Erica N EN Ghneim Khader K Sharma Ashish A Nedellec Rebecca R McKenney Katherine R KR Linde Caitlyn C Broge Thomas T Suscovich Todd J TJ Linnekin Tom T Abbink Peter P Mercado Noe B NB Nkolola Joseph P JP McMahan Katherine K Bondzie Esther A EA Hamza Venous V Peter Lauren L Kordana Nicole N Mahrokhian Shant S Seaman Michael S MS Li Wenjun W Lewis Mark G MG Lauffenburger Douglas A DA Hangartner Lars L Sekaly Rafick-Pierre RP Barouch Dan H DH

Cell 20201001 1

Several HIV-1 and SIV vaccine candidates have shown partial protection against viral challenges in rhesus macaques. However, the protective efficacy of vaccine-elicited polyclonal antibodies has not previously been demonstrated in adoptive transfer studies in nonhuman primates. In this study, we show that passive transfer of purified antibodies from vaccinated macaques can protect naive animals against SIVmac251 challenges. We vaccinated 30 rhesus macaques with Ad26-SIV Env/Gag/Pol and SIV Env g ...[more]

PMID: 33007262

Similar Datasets

Project description:BackgroundZika virus (ZIKV), a mosquito-borne flavivirus, is a re-emerging virus that constitutes a public health threat due to its recent global spread, recurrent outbreaks, and infections that are associated with neurological abnormalities in developing fetuses and Guillain-Barré syndrome in adults. To date, there are no approved vaccines against ZIKV infection. Various preclinical and clinical development programs are currently ongoing in an effort to bring forward a vaccine for ZIKV.Methodology/principle findingsWe have developed a ZIKV vaccine candidate based on Virus-Like-Particles (VLPs) produced in HEK293 mammalian cells using the prM (a precursor to M protein) and envelope (E) structural protein genes from ZIKV. Transient transfection of cells via plasmid and electroporation produced VLPs which were subsequently purified by column chromatography yielding approximately 2mg/L. Initially, immunogenicity and efficacy were evaluated in AG129 mice using a dose titration of VLP with and without Alhydrogel 2% (alum) adjuvant. We found that VLP with and without alum elicited ZIKV-specific serum neutralizing antibodies (nAbs) and that titers correlated with protection. A follow-up immunogenicity and efficacy study in rhesus macaques was performed using VLP formulated with alum. Multiple neutralization assay methods were performed on immune sera including a plaque reduction neutralization test, a microneutralization assay, and a Zika virus Renilla luciferase neutralization assay. All of these assays indicate that following immunization, VLP induces high titer nAbs which correlate with protection against ZIKV challenge.Conclusions/significanceThese studies confirm that ZIKV VLPs could be efficiently generated and purified. Upon VLP immunization, in both mice and NHPs, nAb was induced that correlate with protection against ZIKV challenge. These studies support translational efforts in developing a ZIKV VLP vaccine for evaluation in human clinical trials.

Dataset Information

Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques.

Publications

Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets